Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 9
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Eculizumab versus rituximab in generalised myasthenia gravis.
Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, Öztürk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T. Nelke C, et al. Among authors: huntemann n. J Neurol Neurosurg Psychiatry. 2022 May;93(5):548-554. doi: 10.1136/jnnp-2021-328665. Epub 2022 Mar 4. J Neurol Neurosurg Psychiatry. 2022. PMID: 35246490 Free PMC article.
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Öztürk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T. Nelke C, et al. Among authors: huntemann n. J Neuroinflammation. 2022 Apr 12;19(1):89. doi: 10.1186/s12974-022-02448-4. J Neuroinflammation. 2022. PMID: 35413850 Free PMC article.
Eculizumab treatment alters the proteometabolome beyond the inhibition of complement.
Nelke C, Schroeter CB, Stascheit F, Huntemann N, Pawlitzki M, Willison A, Räuber S, Melzer N, Distler U, Tenzer S, Stühler K, Roos A, Meisel A, Meuth SG, Ruck T. Nelke C, et al. Among authors: huntemann n. JCI Insight. 2023 Jul 10;8(13):e169135. doi: 10.1172/jci.insight.169135. JCI Insight. 2023. PMID: 37227781 Free PMC article.
Validation of TREK1 ion channel activators as an immunomodulatory and neuroprotective strategy in neuroinflammation.
Schroeter CB, Nelke C, Schewe M, Spohler L, Herrmann AM, Müntefering T, Huntemann N, Kuzikov M, Gribbon P, Albrecht S, Bock S, Hundehege P, Neelsen LC, Baukrowitz T, Seebohm G, Wünsch B, Bittner S, Ruck T, Budde T, Meuth SG. Schroeter CB, et al. Among authors: huntemann n. Biol Chem. 2023 Feb 14;404(4):355-375. doi: 10.1515/hsz-2022-0266. Print 2023 Mar 28. Biol Chem. 2023. PMID: 36774650 Free article.
K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies.
Nelke C, Müntefering T, Cengiz D, Theissen L, Dobelmann V, Schroeter CB, Block H, Preuße C, Michels APE, Lichtenberg S, Pawlitzki M, Pfeuffer S, Huntemann N, Zarbock A, Briese T, Kittl C, Dittmayer C, Budde T, Lundberg IE, Stenzel W, Meuth SG, Ruck T. Nelke C, et al. Among authors: huntemann n. J Autoimmun. 2024 Jan;142:103136. doi: 10.1016/j.jaut.2023.103136. Epub 2023 Nov 5. J Autoimmun. 2024. PMID: 37935063 Free article.
20 results